Cardiovascular Evidence for Nattokinase

Introduction

The gap between laboratory promise and clinical proof defines nattokinase’s current status. Decades of research have established that nattokinase dissolves fibrin, lowers blood viscosity, and affects coagulation markers. What remains less clear is whether these biological effects translate into fewer heart attacks, strokes, or cardiovascular deaths. This distinction matters enormously for anyone trying to make evidence-based decisions about their care.

This article examines the actual clinical trial evidence for nattokinase in cardiovascular disease. It addresses what endpoints have been studied, what the trials found, where the evidence falls short, and how the research quality compares to standard cardiovascular therapies. The goal is to provide a clear-eyed assessment that respects both the genuine biological activity of nattokinase and the significant limitations of the current evidence base.

Understanding nattokinase fundamentals provides helpful context for interpreting these trials. For specific endpoints, see the companion articles on atherosclerosis and plaque and blood pressure.

What clinical trials exist for nattokinase in cardiovascular disease?

The clinical evidence consists primarily of small-to-moderate sized trials focused on surrogate endpoints rather than hard clinical outcomes. The largest and most methodologically rigorous is the Nattokinase Atherothrombotic Prevention Study (NAPS), a randomized, placebo-controlled trial of 265 participants followed for three years. This trial assessed carotid intima-media thickness (CIMT) and carotid artery stiffness as imaging markers of subclinical atherosclerosis (Hodis et al., 2021).

Blood pressure trials have been conducted with moderate sample sizes. The most cited is Kim et al.’s randomized controlled trial of 86 participants with pre-hypertension or stage 1 hypertension treated for eight weeks. A 2023 meta-analysis pooled six randomized trials totaling 546 participants to evaluate effects on blood pressure and lipids (Kim et al., 2008; Li et al., 2023).

Observational and retrospective studies provide additional data. A Chinese retrospective analysis of 1,062 participants taking high-dose nattokinase for atherosclerosis and hyperlipidemia reported outcomes over 12 months. An Italian observational study followed 153 patients with vascular disease receiving nattokinase as adjunctive therapy. These studies inform safety and feasibility but cannot establish causation (Chen et al., 2022; Gallelli et al., 2021).

What endpoints have been studied?

Nattokinase trials have examined three main categories of endpoints. The first is fibrinolytic and coagulation markers. Studies have measured D-dimer, fibrinogen, factor VII, factor VIII, euglobulin clot lysis time, and blood viscosity. A crossover trial in healthy volunteers demonstrated that a single dose of nattokinase increases D-dimer and decreases fibrinogen, confirming that the enzyme exerts measurable effects on coagulation parameters (Kurosawa et al., 2015).

The second category is cardiovascular imaging endpoints. The NAPS trial measured CIMT progression and carotid artery stiffness by ultrasound. A smaller Chinese trial used carotid ultrasound to compare nattokinase against simvastatin over 26 weeks. These imaging studies aim to detect changes in atherosclerosis burden as a surrogate for future cardiovascular events (Ren et al., 2017).

The third category is cardiometabolic risk factors. Multiple trials have assessed blood pressure, with the Kim et al. trial showing reductions in systolic and diastolic pressure in hypertensive patients. Lipid effects have also been examined, with some studies reporting modest improvements in total cholesterol, LDL, and triglycerides. A recent trial evaluated nattokinase combined with red yeast rice for lipid-lowering and antithrombotic effects in patients with stable coronary artery disease (Kim et al., 2008; Liu et al., 2024).

What are the study limitations?

The fundamental limitation is the absence of trials powered for hard clinical endpoints. No randomized trial has demonstrated that nattokinase reduces myocardial infarction, stroke, cardiovascular death, or all-cause mortality. The surrogate endpoints studied may or may not predict clinical benefit. CIMT progression, while associated with cardiovascular risk, has proven an inconsistent predictor of treatment effects in drug development.

Sample sizes remain modest even for surrogate endpoint trials. The NAPS trial with 265 participants is the largest. Most other trials enrolled fewer than 100 subjects. Small trials have limited statistical power to detect modest effects and are prone to false-positive findings that fail to replicate. The meta-analysis of blood pressure effects pooled only 546 participants across six trials, which remains far smaller than the evidence base for any guideline-recommended antihypertensive therapy (Li et al., 2023).

Study quality varies considerably. Some trials lack placebo controls, blinding, or intention-to-treat analysis. The large Chinese retrospective study has inherent limitations of observational design including potential confounding and selection bias. Trial durations are typically short, ranging from weeks to months, limiting understanding of long-term effects. Publication bias may favor positive findings, and most research has been conducted in Asian populations, raising questions about generalizability.

How does the evidence quality compare to standard cardiovascular therapies?

The disparity in evidence quality is substantial. Statins have been evaluated in trials enrolling tens of thousands of participants with follow-up of five years or more, demonstrating reductions in major cardiovascular events and mortality. The 4S trial enrolled 4,444 patients. JUPITER enrolled 17,802. These trials used hard endpoints including heart attack, stroke, and death, not imaging surrogates.

Antihypertensive medications similarly rest on large outcome trials. ALLHAT enrolled over 40,000 participants. SPRINT enrolled 9,361. These trials proved that blood pressure lowering with specific drug classes reduces cardiovascular events and mortality. The evidence supporting first-line antihypertensive therapies is orders of magnitude stronger than anything available for nattokinase.

Even newer cardiovascular therapies like PCSK9 inhibitors were evaluated in large outcomes trials before guideline endorsement. FOURIER enrolled 27,564 participants. The nattokinase evidence base does not approach this standard, consisting entirely of small surrogate endpoint studies. This does not mean nattokinase is ineffective, but it does mean the evidence is insufficient to draw confident conclusions about clinical benefit (Chen et al., 2018).

Are there any ongoing trials worth tracking?

The nattokinase research pipeline remains limited compared to pharmaceutical cardiovascular interventions. No large outcomes trials are currently registered. Most ongoing research focuses on mechanistic studies, biomarker effects, or small clinical trials similar to those already completed.

The absence of large trials reflects structural barriers. Nattokinase cannot be patented, eliminating the financial incentive for pharmaceutical companies to fund expensive outcomes trials. Academic funding for supplement research is limited. Regulatory pathways for supplements do not require efficacy trials for market access, removing another driver of rigorous research.

Patients hoping for definitive evidence may face a long wait. The most realistic path to stronger evidence would be an investigator-initiated trial funded by public sources, or perhaps a large pragmatic trial embedded in an existing cardiovascular prevention cohort. Until such studies are conducted, the evidence base will likely expand incrementally through small trials with surrogate endpoints.

Conclusion

Nattokinase has genuine biological activity that produces measurable effects on fibrinolytic markers and blood pressure. The NAPS trial found no benefit for atherosclerosis progression over three years, which represents the most rigorous negative finding in the literature. Blood pressure trials suggest modest effects in hypertensive patients.

What the evidence cannot tell us is whether nattokinase prevents heart attacks, strokes, or cardiovascular death. No trial has been designed or powered to answer these questions. For patients considering nattokinase, this represents the central challenge. The biological plausibility is real. The mechanistic evidence is supportive. The clinical evidence is insufficient.

The next article examines the atherosclerosis evidence in detail, including what the NAPS trial showed about plaque progression and what implications this has for patients with established cardiovascular disease.